Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 17/20 | 0.40 |
| ▸ | CCND1 | P24385 | 17/20 | 0.40 |
| ▸ | CCND3 | P30281 | 17/20 | 0.40 |
| ▸ | CDK6 | Q00534 | 17/20 | 0.40 |
| ▸ | IL1B | P01584 | 2/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29975874 | 1.00 | CDK4 (0.40) | CDK4CCND1CCND3CDK6IL1B | |
| SCHEMBL29326535 | 0.90 | CDK4 (0.38) | CDK4CCND1CCND3CDK6KCNH2 | |
| SCHEMBL29326626 | 0.87 | NLRP3 (0.39) | CDK4CCND1CCND3CDK6KCNH2 | |
| SCHEMBL29326744 | 0.87 | CDK4 (0.38) | CDK4CCND1CCND3CDK6IL1B | |
| SCHEMBL29326571 | 0.86 | MAPK1 (0.37) | CDK4CCND1CCND3CDK6KCNH2 | |
| SCHEMBL29326381 | 0.85 | NLRP3 (0.53) | CDK4CCND1CCND3CDK6IL1B | |
| SCHEMBL30375553 | 0.85 | NLRP3 (0.49) | IL1BKCNH2NLRP3 | |
| SCHEMBL26434542 | 0.85 | NLRP3 (0.49) | IL1BKCNH2NLRP3 | |
| SCHEMBL26093102 | 0.85 | NLRP3 (0.49) | IL1BKCNH2NLRP3 | |
| SCHEMBL29326460 | 0.83 | IL1B (0.44) | CDK4CCND1CCND3CDK6IL1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239758-A1 | SUBSTITUTED TRIAZINE COMPOUND | NICO THERAPEUTICS, INC. | 2024-07-18 | — | — | US | claimed |
| EP-4345097-A1 | SUBSTITUTED TRIAZINE COMPOUND | Astellas Pharma Inc. (JP) | 2024-04-03 | — | — | EP | claimed |
| WO-2022230912-A1 | SUBSTITUTED TRIAZINE COMPOUND | アステラス製薬株式会社 | 2022-11-03 | — | — | WO | claimed |
| US-20240239758-A1 | SUBSTITUTED TRIAZINE COMPOUND | NICO THERAPEUTICS, INC. | 2024-07-18 | — | — | US | disclosed |
| US-20240239758-A1 | SUBSTITUTED TRIAZINE COMPOUND | NICO THERAPEUTICS, INC. | 2024-07-18 | — | — | US | disclosed |
| EP-4345097-A1 | SUBSTITUTED TRIAZINE COMPOUND | Astellas Pharma Inc. (JP) | 2024-04-03 | — | — | EP | disclosed |
| WO-2022230912-A1 | SUBSTITUTED TRIAZINE COMPOUND | アステラス製薬株式会社 | 2022-11-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239758-A1 | SUBSTITUTED TRIAZINE COMPOUND | NLRP3, NLRP1, PYCARD | CDK4 2774/4885CCND1 4369/4885CCND3 4525/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.